| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 29,050 | 124,800 | 61,280 | 55,290 | 23,800 |
| Sales Growth | -76.72% | +103.66% | +10.83% | +132.31% | unch |
| Net Income | -171,980 | 4,348,930 | -1,009,030 | -845,260 | -809,230 |
| Net Income Growth | -103.95% | +531.00% | -19.38% | -4.45% | unch |
Roivant Sciences Ltd
(ROIV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Fiscal Year End Date: 03/31